This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Beckman Research Institute, City of Hope. Active years: 2021-2023.
Company Filing History:
Years Active: 2021-2023
Title: The Innovative Contributions of Elizabeth Epps
Introduction
Elizabeth Epps is a notable inventor based in Mission Viejo, CA. She has made significant contributions to the field of biotechnology, particularly in the development of lentiviral vectors. With a total of 2 patents, her work has the potential to advance gene therapy techniques.
Latest Patents
Epps' latest patents include innovative methods involving splice inhibiting oligonucleotides. One patent provides oligonucleotides, kits, and methods useful for increasing lentiviral titers. The second patent focuses on microRNAs embedded within an intron, known as 'mirtrons,' which can be utilized as a platform for expressing shRNA or miRNA mimics in a lentiviral vector. The inventors developed a strategy to enhance lentiviral titering by reducing the production of shRNA/miRNA from the vector during packaging. This is achieved through the introduction of splice-inhibiting antisense oligonucleotides during vector packaging, which inhibit the splicing of the mirtron and subsequent processing of the shRNAs/miRNAs. Additionally, a kit comprising an oligonucleotide with a mirtron splice site binding sequence and a lentiviral packaging system is provided. The method for producing a lentivirus involves transfecting a cell with this oligonucleotide, thereby producing the lentivirus.
Career Highlights
Elizabeth Epps is currently associated with City of Hope, where she continues her research and development efforts. Her work has garnered attention for its innovative approach to enhancing gene therapy techniques.
Collaborations
Epps has collaborated with notable colleagues, including John C. Burnett and John J. Rossi, who have contributed to her research endeavors.
Conclusion
Elizabeth Epps is a pioneering inventor whose work in splice inhibiting oligonucleotides is paving the way for advancements in lentiviral vector technology. Her contributions are significant in the field of biotechnology and hold promise for future applications in gene therapy.